AI-generated summary
In this randomized, placebo-controlled trial of 120 breast cancer patients receiving radiotherapy, the authors report that photobiomodulation therapy was associated with a lower incidence of moist desquamation at the end of radiotherapy (7% versus 30% in the control group). Biophysical skin measurements of water loss, erythema and melanin also showed smaller changes in the treated group.
- Participants
- 120
- Who or what was studied
- Breast cancer patients undergoing radiotherapy after lumpectomy
- Wavelengths
- 808, 905 nm
- Limits stated in the abstract
- The abstract reports a single trial and does not describe limits beyond the randomized, placebo-controlled design.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nm, 905 nm
- Energy density (fluence)
- 4 J/cm2
- Power density (irradiance)
- 168 mW/cm2
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Randomized controlled trial, Placebo-controlled, Fluence, Melanin, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.